Inducing Immunity Where It Matters: Orthotopic HPV Tumor Models and Therapeutic Vaccinations

被引:14
作者
Zottnick, Samantha [1 ,2 ,3 ]
Voss, Alessa L. [1 ,2 ]
Riemer, Angelika B. [1 ,2 ]
机构
[1] German Canc Res Ctr, Immunotherapy & Immunoprevent, Heidelberg, Germany
[2] German Ctr Infect Res DZIF, Mol Vaccine Design, Partner Site Heidelberg, Heidelberg, Germany
[3] Heidelberg Univ, Fac Biosci, Heidelberg, Germany
来源
FRONTIERS IN IMMUNOLOGY | 2020年 / 11卷
关键词
HPV; orthotopic tumor models; therapeutic vaccination; tissue-resident T cells; MHC-humanized mice; T-CELLS; MOUSE MODEL; INTRAVAGINAL IMMUNIZATION; VACCINE; CANCER; CD8; RESPONSES; ANTIGEN; MICE; REGRESSION;
D O I
10.3389/fimmu.2020.01750
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Anogenital and oropharyngeal cancers caused by human papillomavirus (HPV) infections account for 4.5% of all cancer cases worldwide. So far, only the initial infection with selected high-risk types can be prevented by prophylactic vaccination. Already existing persistent HPV infections, however, can currently only be treated by surgical removal of resulting lesions. Therapeutic HPV vaccination, promoting cell-based anti-HPV immunity, would be ideal to eliminate and protect against HPV-induced lesions and tumors. A multitude of vaccination approaches has been tested to date, many of which led to high amounts of HPV-specific T cellsin vivo. However, growing evidence suggests that not the induction of systemic but of local immunity is paramount for tackling mucosal infections and tumors. Therefore, recent therapeutic vaccination studies have focused on how to induce tissue-resident T cells in the anogenital and oropharyngeal mucosa. These approaches include direct mucosal vaccinations and influencing the migration of systemic T cells toward the mucosa. The efficacy of these new vaccination approaches is best testedin vivoby utilizing orthotopic tumor models, i.e. HPV-positive tumors being located in the animal's mucosa. In line with this, we here review existing HPV tumor models and describe two novel tumorigenic cell lines for the MHC-humanized mouse model A2.DR1. These were used for the establishment of an HPV16 E6/E7-positive vaginal tumor model, suitable for testing therapeutic vaccines containing HLA-A2-restricted HPV16-derived epitopes. The newly developed MHC-humanized orthotopic HPV16-positive tumor model is likely to improve the translatability ofin vivofindings to the clinical setting.
引用
收藏
页数:8
相关论文
共 66 条
[1]   Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses [J].
Bagarazzi, Mark L. ;
Yan, Jian ;
Morrow, Matthew P. ;
Shen, Xuefei ;
Parker, R. Lamar ;
Lee, Jessica C. ;
Giffear, Mary ;
Pankhong, Panyupa ;
Khan, Amir S. ;
Broderick, Kate E. ;
Knott, Christine ;
Lin, Feng ;
Boyer, Jean D. ;
Draghia-Akli, Ruxandra ;
White, C. Jo ;
Kim, J. Joseph ;
Weiner, David B. ;
Sardesai, Niranjan Y. .
SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (155)
[2]   Successful application of prime and pull strategy for a therapeutic HSV vaccine [J].
Bernstein, David, I ;
Cardin, Rhonda D. ;
Bravo, Fernando J. ;
Awasthi, Sita ;
Lu, Peiwen ;
Pullum, Derek A. ;
Dixon, David A. ;
Iwasaki, Akiko ;
Friedman, Harvey M. .
NPJ VACCINES, 2019, 4 (1)
[3]   Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system [J].
Berraondo, Pedro ;
Nouze, Clemence ;
Preville, Xavier ;
Ladant, Daniel ;
Leclerc, Claude .
CANCER RESEARCH, 2007, 67 (18) :8847-8855
[4]   Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours [J].
Bialkowski, Lukasz ;
van Weijnen, Alexia ;
Van der Jeught, Kevin ;
Renmans, Dries ;
Daszkiewicz, Lidia ;
Heirman, Carlo ;
Stange, Geert ;
Breckpot, Karine ;
Aerts, Joeri L. ;
Thielemans, Kris .
SCIENTIFIC REPORTS, 2016, 6
[5]   Cooperation of genes in HPV16 E6/E7-dependent cervicovaginal carcinogenesis trackable by endoscopy and independent of exogenous estrogens or carcinogens [J].
Bottinger, Paula ;
Schreiber, Karin ;
Hyjek, Elizabeth ;
Krausz, Thomas ;
Spiotto, Michael T. ;
Steiner, Madeline ;
Idel, Christian ;
Booras, Heather ;
Beck-Engeser, Gabriele ;
Riederer, Jessie ;
Willimsky, Gerald ;
Wolf, Steven P. ;
Karrison, Theodore ;
Jensen, Elizabeth ;
Weichselbaum, Ralph R. ;
Nakamura, Yusuke ;
Yew, Poh Yin ;
Lambert, Paul F. ;
Kurita, Takeshi ;
Kiyotani, Kazuma ;
Leisegang, Matthias ;
Schreiber, Hans .
CARCINOGENESIS, 2020, 41 (11) :1605-1615
[6]   Therapeutic vaccines for high-risk HPV-associated diseases [J].
Chabeda, Aleyo ;
Yanez, Romana J. R. ;
Lamprecht, Renate ;
Meyers, Ann E. ;
Rybicki, Edward P. ;
Hitzeroth, Inga I. .
PAPILLOMAVIRUS RESEARCH, 2018, 5 :46-58
[7]   BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses [J].
Cho, Hyun-Il ;
Barrios, Kelly ;
Lee, Young-Ran ;
Linowski, Angelika K. ;
Celis, Esteban .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (04) :787-799
[8]   Recent advances in preclinical model systems for papillomaviruses [J].
Christensen, Neil D. ;
Budgeon, Lynn R. ;
Cladel, Nancy M. ;
Hu, Jiafen .
VIRUS RESEARCH, 2017, 231 :108-118
[9]   Current status of therapeutic HPV vaccines [J].
Clark, Katharine T. ;
Trimble, Cornelia L. .
GYNECOLOGIC ONCOLOGY, 2020, 156 (02) :503-510
[10]   A Prime-Pull-Amplify Vaccination Strategy To Maximize Induction of Circulating and Genital-Resident Intraepithelial CD8+ Memory T Cells [J].
Cuburu, Nicolas ;
Kim, Rina ;
Guittard, Geoffrey C. ;
Thompson, Cynthia D. ;
Day, Patricia M. ;
Hamm, David E. ;
Pang, Yuk-Ying S. ;
Graham, Barney S. ;
Lowy, Douglas R. ;
Schiller, John T. .
JOURNAL OF IMMUNOLOGY, 2019, 202 (04) :1250-1264